Systemic lupus erythematosus (SLE) is a complex autoimmune disease, and abnormal B-cell function plays a key role in its pathogenesis. Multiple epigenetic mechanisms, such as DNA methylation, histone modification, and non-coding RNAs, can regulate B cell development, differentiation, and function. This review outlines the relationship between the epigenetic regulation of B cells and the pathogenesis of SLE and prospectively discusses possible therapeutic approaches.
SiegelCHSammaritanoLR. Systemic lupus erythematosus: a review. JAMA2024; 331: 1480–1491.
2.
TangyeSGNguyenTDeenickEK, et al.Inborn errors of human B cell development, differentiation, and function. J Exp Med2023; 220: e20221105.
3.
WuHDengYFengY, et al.Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity. Cell Mol Immunol2018; 15: 676–684.
4.
MooreLDLeTFanG. DNA methylation and its basic function. Neuropsychopharmacology2013; 38: 23–38.
5.
LiYMaCLiaoS, et al.Combined proteomics and single cell RNA-sequencing analysis to identify biomarkers of disease diagnosis and disease exacerbation for systemic lupus erythematosus. Front Immunol2022; 13: 969509.
6.
SteriMOrrùVIddaML, et al.Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med2017; 376: 1615–1626.
7.
ZhaoMWuXZhangQ, et al.RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res Ther2010; 12: R227.
8.
TanakaSIseWInoueT, et al.Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity. Nat Immunol2020; 21: 950–961.
9.
GaraudSLe DantecCJousse-JoulinS, et al.IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol2009; 182: 5623–5632.
10.
NakkuntodJSukkapanPAvihingsanonY, et al.DNA methylation of human endogenous retrovirus in systemic lupus erythematosus. J Hum Genet2013; 58: 241–249.
11.
BreitbachMERamakerRCRobertsK, et al.Population-specific patterns of epigenetic defects in the B cell lineage in patients with systemic lupus erythematosus. Arthritis Rheumatol2020; 72: 282–291.
12.
SelviBRMohankrishnaDVOstwalYB, et al.Small molecule modulators of histone acetylation and methylation: A disease perspective. Biochim Biophys Acta2010; 1799: 810–828.
13.
RamaiahMJTanguturADManyamRR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci2021; 277: 119504.
14.
JohnsonKAngelin-DuclosCParkS, et al.Changes in histone acetylation are associated with differences in accessibility of V(H) gene segments to V-DJ recombination during B-cell ontogeny and development. Mol Cell Biol2003; 23: 2438–2450.
15.
GautamPSharmaABhatnagarA. Global histone modification analysis reveals hypoacetylated H3 and H4 histones in B cells from systemic lupus erythematosus patients. Immunol Lett2021; 240: 41–45.
16.
FanJIwataSTanakaY, et al.Kdm5a promotes B cell activation in systemic lupus erythematosus via downregulation of A20 by histone modification. Pathol Res Pract2021: 153653.
17.
MeiYXinYLiX, et al.Aberrant expression of JMJD3 in SLE promotes B-cell differentiation. Immunobiology (1979)2023; 228: 152347.
18.
NemethKBayraktarRFerracinM, et al.Non-coding RNAs in disease: From mechanisms to therapeutics. Nat Rev Genet2024; 25: 211–232.
19.
HuangBGuoFChenJ, et al.Regulation of B-cell function by miRNAs impacting systemic lupus erythematosus progression. Gene (Amst)2025; 933: 149011.
20.
ZhangFWuLQianJ, et al.Identification of the long noncoding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus. J Autoimmun2016; 75: 96–104.
21.
GuXTohmeRTomlinsonB, et al.Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia2021; 35: 1023–1036.
22.
KaganABGarrisonDAAndersNM, et al.DNA methyltransferase inhibitor exposure-response: Challenges and opportunities. Clin Transl Sci2023; 16: 1309–1322.
23.
BaladaEOrdi-RosJSerrano-AcedoS, et al.Transcript levels of DNA methyltransferases DNMT1, DNMT3A and DNMT3B in CD4+ T cells from patients with systemic lupus erythematosus. Immunology (Oxf)2008; 124: 339–347.
24.
DanbaraMKameyamaKHigashiharaM, et al.DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines. Mol Immunol2002; 38: 1161–1166.
25.
ZhangQDingSZhangH, et al.Increased Set1 binding at the promoter induces aberrant epigenetic alterations and up-regulates cyclic adenosine 5′-monophosphate response element modulator alpha in systemic lupus erythematosus. Clin Epigenet2016; 8: 126.
26.
LiHTsokosMGBickertonS, et al.Precision DNA demethylation ameliorates disease in lupus-prone mice. JCI Insight2018; 3: e120880.
27.
ParveenRHariharDChatterjiBP. Recent histone deacetylase inhibitors in cancer therapy. Cancer2023; 129: 3372–3380.
28.
Da CostaTPEl-CheikhMCCarneiroK. Epigenetic therapy as a putative molecular target to modulate B cell biology and behavior in the context of immunological disorders. J Immunol Res2020; 2020: 1589191.
29.
MishraNReillyCMBrownDR, et al.Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Investig2003; 111: 539–552.
30.
SouliotisVLVougasKGorgoulisVG, et al.Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus. Arthritis Res Ther2016; 18: 182.
31.
WaibelMChristiansenAJHibbsML, et al.Manipulation of B-cell responses with histone deacetylase inhibitors. Nat Commun2015; 6: 6838.
32.
RegnaNLViesonMDLuoXM, et al.Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol2016; 162: 58–73.
33.
ChoiEWSongJWHaN, et al.CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus. Sci Rep2018; 8: 17297.
34.
SanchezHNMoroneyJBGanH, et al.B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids. Nat Commun2020; 11: 60.
35.
MaZChenLWangY, et al.Novel insights of EZH2-mediated epigenetic modifications in degenerative musculoskeletal diseases. Ageing Res Rev2023; 90: 102034.
36.
YuLWangYFXiaoJ, et al.Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition. Acta Pharmacol Sin2023; 44: 2113–2124.
37.
ZhangMIwataSHajimeM, et al.Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC Homolog 2 by the methyltransferase EZH2. Arthritis Rheumatol2020; 72: 1143–1153.
38.
ChaTLZhouBPXiaW, et al.Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science2005; 310: 306–310.
39.
ViréEBrennerCDeplusR, et al.The Polycomb group protein EZH2 directly controls DNA methylation. Nature2006; 439: 871–874.
40.
GaoJFosbrookCGibsonJ, et al.Review: Targeting EZH2 in neuroblastoma. Cancer Treat Rev2023; 119: 102600.
41.
WuLJiangXQiC, et al.EZH2 inhibition interferes with the activation of Type I interferon signaling pathway and ameliorates lupus nephritis in NZB/NZW F1 mice. Front Immunol2021; 12: 653989.
42.
RohraffDMHeYFarkashEA, et al.Inhibition of EZH2 ameliorates lupus-like disease in MRL/lpr mice. Arthritis Rheumatol2019; 71: 1681–1690.
43.
TsouPSCoitPKilianNC, et al.EZH2 modulates the DNA methylome and controls T cell adhesion through junctional adhesion molecule A in lupus patients. Arthritis Rheumatol2018; 70: 98–108.
44.
SuSTYingHYChiuYK, et al.Involvement of histone demethylase LSD1 in Blimp-1-mediated gene repression during plasma cell differentiation. Mol Cell Biol2009; 29: 1421–1431.
45.
SunamiYYokoyamaTYoshinoS, et al.BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes. Blood Adv2022; 6: 1827–1843.
46.
MontanoENBoseMHuoL, et al.α-Ketoglutarate-dependent KDM6 histone demethylases and interferon-stimulated gene expression in lupus. Arthritis Rheumatol2024; 76: 396–410.
47.
ZhouSWangYMengY, et al.In vivo therapeutic success of MicroRNA-155 antagomir in a mouse model of lupus alveolar hemorrhage. Arthritis Rheumatol2016; 68: 953–964.
48.
PanYJiaTZhangY, et al.MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int J Nanomed2012; 7: 5957–5967.
49.
WangMChenHQiuJ, et al.Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development. J Autoimmun2020; 109: 102440.
50.
GuoHMaJZhangY, et al.Delivery of AntagomiR-7 through polymer nanoparticles for assisting B cell to alleviate systemic lupus erythematosus. Front Bioeng Biotechnol2023; 11: 1180302.
